StemCells, Inc. to Present at Leading Conference on Neuroregeneration in
NEWARK, Calif., Oct. 22, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc.
(Nasdaq:STEM), the leading stem cell company developing novel cell-based
therapeutics for disorders of the central nervous system, announced today that
Ann Tsukamoto, Ph.D., Executive Vice President, Scientific and Strategic
Alliances at StemCells, will speak at the B-Debate International Center for
Scientific Debate Barcelona,to be held October 23-24 in Barcelona, Spain. Dr.
Tsukamoto will participate on October 23 in the forum "Neuroregeneration: Is
There Already A Translational Experience in Clinical Practice?" and will make
a presentation on the Company's clinical development programs.
The goal of the B-Debate International Center for Scientific Debate Barcelona
is to promote the exchange of information about neuroregeneration among
cutting edge researchers in basic science, translational research, and
clinical innovation.The B-Debate is organized by BIOCAT, the organization
that coordinates and promotes the biotechnology, biomedicine, and medical
technology sector in Catalonia, and La Caixa Foundation, in collaboration with
the Institute Guttmann, a leading hospital for the treatment and
rehabilitation of patients with spinal cord injury, brain damage, or other
serious neurological disability. The Institute Guttmann is affiliated with the
Autonomous University of Barcelona.
About StemCells, Inc.
StemCells, Inc. is engaged in the research, development, and commercialization
of cell-based therapeutics and tools for use in stem cell-based research and
drug discovery. The Company's proprietary HuCNS-SC® cells (purified human
neural stem cells) are currently in development as a potential treatment for a
broad range of central nervous system disorders.In a PhaseI clinical trial
in Pelizaeus-Merzbacher disease (PMD), a fatal myelination disorder in
children, the Company has shown preliminary evidence of progressive and
durable donor-derived myelination in all four patients transplanted with
HuCNS-SC cells.The Company is conducting a Phase I/II clinical trial in
chronic spinal cord injury in Switzerland, Canada and the United States, and
has reported positive interim data for the first three patients.The Company
is also conducting a Phase I/II clinical trial in dry age-related macular
degeneration (AMD) in the United States. In addition, the Company is pursuing
preclinical studies in Alzheimer's disease, with support from the California
Institute for Regenerative Medicine (CIRM).StemCells also markets stem cell
research products, including media and reagents, under the SC Proven®
brand.Further information about StemCells is available at
Apart from statements of historical fact, the text of this press release
constitutes forward-looking statements within the meaning of the U.S.
securities laws, and is subject to the safe harbors created therein.These
statements include, but are not limited to, statements regarding the clinical
development of the Company's HuCNS-SC cells and the future business operations
of the Company. These forward-looking statements speak only as of the date of
this news release. The Company does not undertake to update any of these
forward-looking statements to reflect events or circumstances that occur after
the date hereof. Such statements reflect management's current views and are
based on certain assumptions that may or may not ultimately prove valid. The
Company's actual results may vary materially from those contemplated in such
forward-looking statements due to risks and uncertainties to which the Company
is subject, including the factors that are described under the heading "Risk
Factors" in the Company's Annual Report on Form10-K for the year ended
December 31, 2012 and in its subsequent reports on Forms 10-Q and 8-K.
CONTACT: Rodney Young
Chief Financial Officer
Press spacebar to pause and continue. Press esc to stop.